Vascular calcification (VC) strongly correlates with declining renal function and contributes to the high morbidity and mortality of patients with CKD (chronic kidney disease). It is closely regulated by circulating factors but little is known about the capacity of serum from patients to induce calcification outside the disease setting, which we now define as the calcific potential of serum. We have therefore examined the ability of serum from age-and sex-matched subjects with and without advancing CKD to induce calcification of cultured SMCs (smooth muscle cells). Samples from patients with CKD induced significant calcification compared with controls. More importantly, samples from patients on haemodialysis induced significantly higher calcification than those with moderate or advanced CKD. The calcification induced by the latter two but not those on haemodialysis could be enhanced with calcium chloride and β-GP (β-glycerophosphate). A positive correlation was evident between measured serum creatinine, phosphate, PTH (parathyroid hormone), OPG (osteoprotegerin) and the degree of calcification in vitro. eGFR (estimated glomerular filtration rate), DBP (diastolic blood pressure), haemoglobin and serum albumin correlated negatively. Stepwise multivariate analysis of log-transformed calcific potential data highlighted serum creatinine, albumin and OPG as significant predictors, explaining approximately 50 % of the variation. Thus, other regulators, either not investigated or as yet unidentified, may contribute to the calcification potential of serum in vitro. Furthermore, uraemic serum can induce graded calcification outside of the disease milieu that reflects the degree of kidney impairment in vivo. These findings could have important clinical relevance in terms of developing novel diagnostic and/or therapeutic strategies for subjects with CKD.
INTRODUCTION
Calcification is a common occurrence in end-stage renal failure and shows a strong correlation with declining renal function [1] . It often results in a diverse range of pathologies including calcific uraemic arteriolopathy, solid as well as extra-osseous soft tissue calcification of which VC (vascular calcification) is the most common and often the most clinically relevant corollary. The existence of VC in CKD (chronic kidney disease) results in increased arterial stiffness, becoming predictive of secondary cardiovascular complications with high morbidity and mortality [2, 3] .
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The precise mechanisms that lead to VC in CKD subjects are poorly understood but it is accepted to be a delicate and well-controlled biological process that results in SMCs (smooth muscle cells) gaining an osteoblastic phenotype [4] . These complex changes may be regulated in vivo by circulating factors in plasma and, interestingly, in vitro by uraemic serum especially under hyperphosphataemic conditions [5] . The latter demonstrates that serum from pathological settings may have a potential to induce VC even outside the disease milieu and provides a means through which the mechanisms associated with this process can be investigated. More importantly, the ability of serum to induce calcification in vitro could be exploited to predict the risk of calcification in vivo during routine tests, and applied to the clinical management of patients. To achieve this, a robust biological model is required in which the calcific potential of individual serum samples can be validated, and trends within defined groups of CKD patients identified to allow the establishment of threshold scores which might guide the need for intervention.
We have developed an in vitro model of calcification in SMCs and embarked on a programme of studies to establish the calcific potential (i.e. ability to induce calcification) of individual serum samples from cohorts of patients with CKD. More specifically, we have investigated whether serum from patients with stages 3, 4/5 CKD or on haemodialysis (5D) has a greater in vitro calcific potential than normal age-and sex-matched controls. We also wished to establish whether in vitro calcific potential correlated with the degree of renal impairment. In parallel, we have characterized each patient in terms of disease vintage, extrarenal co-morbidity and smoking history. Furthermore, we have related the calcific potential of serum in individuals to the levels of biochemical markers and report for the first time that CKD serum induces graded calcification outside of the disease milieu that correlates with the degree of kidney impairment, and with specific biomarkers which may, in part, explain the potential of serum to induce calcification in vitro.
MATERIALS AND METHODS

Ethical approval
Ethical approval was obtained from the Hertfordshire Research Ethics Committee. The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. The study subjects gave written informed consent prior to recruitment into the study. All animal care and experimental procedures complied with the UK Home Office Animal (Scientific Procedures) Act 1986 and to local ethical review processes.
Patient recruitment
All the patients were recruited from the renal clinics in East and North Herts NHS Trust hospitals in Hertfordshire, UK. Inclusion criteria for the patients with CKD were age >18 years, eGFR (estimated glomerular filtration rate) by MDRD-4 (Modification of Diet in Renal Disease-4) formula less than 60 ml/min. Exclusion criteria were immunosuppressive therapy, pregnancy, hormone replacement therapy and malignancy. A total of 20 age-and sexmatched healthy individuals with normal renal function, without diabetes or in vivo calcification as detected by a CT (computed tomography) scan were recruited as controls. There were 70 subjects in the patient group who, based on eGFR, were classified into a moderate (stage 3 CKD; 21 subjects), advanced (stage 4 and 5 CKD; 18 subjects) or haemodialysis group (5D; 30 subjects). In the 5D group, only those patients who had undergone at least 3 months of dialysis were considered.
Data collection
Demographic and clinical variables including age, gender and BP (blood pressure) were recorded. Blood samples in controls and pre-dialysis patients were collected during routine visits and those of haemodialysis patients were collected immediately before dialysis sessions. Samples were taken into Z serum sep clot activator VACUTTE ® , centrifuged at 2000 g for 15 min at 4
• C and the serum stored at − 80
• C until analysed.
Biochemical analysis
Routine biochemistry analyses were conducted for urea, creatinine and CRP (C-reactive protein). Levels of the latter >5 mg/l were considered high. PTH (parathyroid hormone) concentrations were measured on the Beckman Access ® 2 immunoassay system (Beckman Coulter). Assays for OPG (osteoprotegerin), RANKL (receptor activator of nuclear factor κB ligand) and BAP (bone alkaline phosphatase) were performed on the automated ELISA analyser Triturus ® (Grifols). MGP (matrix Gla protein) was quantified using the BIOMEDICA GRUPEE kit (BI-20062). All analyses were performed in duplicate.
Isolation and culture of RASMCs (rat aortic SMCs) Cells were isolated as described previously [6] using aortic explants obtained from male Wister rats and cultured in complete culture medium consisting of DMEM (Dulbecco's modified Eagle's medium) supplemented with penicillin (100 units/ml), streptomycin (100 μg/ml) and 10 % (v/v) FBS (fetal bovine serum). Confluent monolayers were routinely passaged using trypsin/EDTA (0.01/0.02 % in PBS) and sub-cultured to confluence over a period of no more than 3-4 days in a new culture flask.
Induction of calcification in RASMCs
All experiments were carried out using cells at passage 3-5 and at a confluence of 60-70 % in 96-well plates. To determine the optimum time point for calcification, cells were initially incubated for 1-7 days with a calcification buffer made up by adding 7 mM CaCl 2 plus 7 mM β-GP (β-glycerophosphate) to the complete culture medium which already had 1.8 mM calcium and 0.9 mM sodium hydrogen phosphate as standard. These additions brought the final concentration of CaCl 2 and β-GP to 8.8 mM and 7.9 mM respectively and are well within the range used in many other in vitro calcification studies [7, 8] .
To determine the calcification potential of human serum from control and CKD settings, cells were incubated with 10 % (v/v) serum added to standard DMEM supplemented with only penicillin (100 units/ml) and streptomycin (100 μg/ml). In parallel studies 7 mM CaCl 2 and 7 mM β-GP were also added to determine whether the calcification potential of the serum could be enhanced within a calcifying milieu.
To ensure that any subsequent mineralization was regulated and reflective of genuine calcification of cells rather than nonphysiological spontaneous precipitation of excess calcium phosphate, parallel experiments were carried out where CaCl 2 (7 mM) and β-GP (7 mM) were incubated either in empty wells or with cells fixed with 10 % (v/v) formaldehyde. All incubations were terminated after the designated time period, which varied from 1 to 7 days.
Determination of calcification and total cell protein content
Cell monolayers were lysed with buffer consisting of 10 mM Tris/HCl (pH 7.4) and 10 % (w/v) SDS. Calcification was determined using the DICA-500 Ca 2 + assay kit from Bioassay System (Universal Biologicals), according to the manufacturer's instructions. Total protein content was measured using the BCA (bicinchoninic acid) protein assay as described previously [9] . Once determined, calcium levels in lysates were normalized for total cell protein per well and the data presented as nmol of Ca 2 + /mg of protein.
In parallel experiments, cells were viewed at ×10 magnification using a Nikon confocal microscope under normal view to visualize plaques formed as a consequence of calcification.
Cell viability assay
Cell viability was determined under the different experimental conditions by assessing the metabolism of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] to formazan as described previously [9] .
Statistical analysis
Statistical analysis was carried out using SPSS version 17 and the data are presented as means + − S.D. for normally distributed data and as medians (interquartile range) if not normally distributed. For continuous variables the significance of differences between two groups was determined using a Student's t test (for normally distributed data) and the Mann-Whitney U tests (for non-normally distributed data). One-way ANOVA followed by Bonferroni post-hoc testing or the Kruskal-Wallis test was used to compare multiple groups as appropriate. The χ 2 test was used to differentiate between the groups with respect to categorical data. Correlations utilized the Pearson and Spearman test as appropriate. For multivariate analysis, values of calcific potential were log-transformed.
Materials
Cell culture and other general biochemical reagents including CaCl 2 and β-GP were purchased from Sigma-Aldrich. Penicillin and streptomycin was from Fisher Scientific and FBS from Gibco. The BCA protein quantification kit was from Thermo Scientific. Reagents for OPG, RANKL, BAP were obtained from Oxford Biosystems.
RESULTS
Demographics and clinical factors
All subjects were Caucasian. There were no significant differences in the age or gender ratios across the groups. SBP (systolic BP) was significantly lower in the 5D group than in patients with advanced CKD, and DBP (diastolic BP) was significantly lower in the 5D than in both pre-dialysis groups (Table 1) .
Baseline biochemistry and haematology
CKD groups differed significantly from controls with respect to haemoglobin, serum albumin, cholesterol, phosphate, PTH, OPG and RANKL levels and with respect to the OPG/RANKL ratio (Table 1) . Serum phosphate increased with advancing CKD, whereas serum calcium was unchanged. Haemoglobin levels were higher in moderate CKD than in the 5D group. Serum albumin was higher in both moderate and advanced CKD groups than in 5D patients. Likewise the proportion with elevated CRP levels was greater in the 5D group than in both other CKD groups. BAP levels were similar in all CKD groups. PTH and OPG levels were significantly higher in 5D patients than both pre-dialysis groups, whereas RANKL levels and OPG/RANKL ratios did not differ significantly between CKD stages. MGP has so far been determined only in the 5D group in which levels were significantly lower than in controls ( Table 1) .
Development of an in vitro model of calcification
In order to be able to determine the effects of serum from human patients on the development of VC, an in vitro model of this process was initially established using RASMCs exposed to CaCl 2 and β-GP as a phosphate source. Each compound was used at a concentration of 7 mM and this was predetermined from pilot studies using 2-20 mM of either component. At 2 mM there was little or no evidence of calcification, whereas at higher concentration ( 15 mM) calcium precipitated with β-GP in the medium (results not shown). A 7 mM concentration of each combined was found to give consistent and optimum calcification. As shown in Figure 1 (A), incubation of cells for 5 days with complete culture medium supplemented with 10 % (v/v) FBS resulted in marginal calcification. Inclusion of 7 mM CaCl 2 enhanced calcification while β-GP (7 mM) was without significant effect. By comparison, inclusion of both together caused a marked increase in the calcification, which was much greater than the additive effects.
Photographs taken of cells following the different treatment conditions ( Figure 1B ) revealed a normal monolayer under control conditions with little evidence of calcification as indicated by the lack of calcific plaques. Incubations with CaCl 2 at 7 mM showed moderate plaque formation, whereas cells incubated with β-GP exhibited less marked effects. Consistent with the calcification data ( Figure 1A ), co-incubations with CaCl 2 and β-GP (both at 7 mM) caused marked calcific plaque formation throughout the monolayer ( Figure 1B) .
In parallel studies, the time course of calcification was determined over 7 days. The results in Figure 1 (C) show a timedependent increase, which was evident after day 3, reaching a peak at day 5 but declining by day 7. This trend was only evident when cells were incubated with CaCl 2 together with β-GP. The basal levels of calcification seen with culture medium alone did not change significantly over time ( Figure 1C ).
Assessment of cell viability using the MTT assay showed that survival was unaffected at days 1-5 but was significantly reduced at day 7 as reflected by the marked inhibition of MTT metabolism to formazan ( Figure 1D ). This decrease in cell viability may account for the decreases in calcification observed at day 7 and as a result all subsequent experiments were carried out over a 5-day period. 
Effects of human serum on calcification of RASMCs
Incubation of cells with serum from patients with CKD induced calcification of RASMCs outside the disease milieu. More importantly, there was a graded response in total cellular calcium content and deposition of calcium phosphate crystals. These changes, which we have defined as the calcific potential of serum, correlated with the degree of renal impairment. This is clearly evident in Figure 2 that shows that serum from 5D patients had a greater calcific potential than serum obtained from stage 3 or stage 4/5. Control human serum did not cause any obvious calcification of cell monolayers and the total detected levels of calcium (50.8 + − 9.3 nmol of Ca 2 + /mg of protein) were not significantly different to those in cells incubated with FBS (32.2 + − 8.4 nmol of Ca 2 + /mg of protein; P = 0.30). These levels are consistent with other studies in SMCs [10, 11] . However, the degree of calcification in our studies was less, perhaps due to the difference in the species and incubation period.
In the whole group, the calcific potential of serum correlated positively with blood urea, serum creatinine, phosphate, OPG and PTH, and negatively with DBP, haemoglobin and albumin (Table 2) . In stepwise multivariate analysis the significant predictors of log-transformed calcific potential were serum creatinine (P < 0.001), albumin (P = 0.009) and OPG (P = 0.010). These factors however only explain approximately 50 % of the variation in calcific potential (r 2 = 0.506). Other parameters including age, serum cholesterol, phosphate, PTH and high CRP were not significant in this model. The calcific potential of serum could therefore be influenced by other as yet unidentified factors.
In view of the graded response reported above, we were interested in establishing whether the calcific potential of the stages 3, 4/5 or 5D sera could be enhanced under conditions that may be associated with calcification in vivo (such as the presence of high calcium and phosphate). We therefore investigated the effects of co-incubating RASMCs with serum samples and both CaCl 2 (7 mM) and β-GP (7 mM). In these studies, control serum negated calcification even in the presence of CaCl 2 and β-GP, suggesting an inherent ability to protect cells from being calcified. In contrast with the observations with control serum, the calcific potential of serum from stage 3 and 4/5 CKD groups was significantly enhanced, whereas no significant increment was apparent with the 5D samples ( Figure 3) . Interestingly, within the latter (5D group) we observed that half of the samples (referred to here as responders) did show an increase in calcification above that seen with serum alone when co-incubated with CaCl 2 and β-GP, whereas the other half (non-responders) did not (Figure 4) . What was even more striking was that responders had significantly higher levels of MGP (P = 0.003), HDL (high-density lipoprotein; P = 0.004) and RANKL (P = 0.012) when compared with the non-responders. Serum phosphate was lower and serum albumin higher in the responders, but this did not attain statistical significance. Levels of other potential modulators of calcification in Table 1 were not significantly different between the two groups. Induction of calcification and assay for cytotoxicity in RASMCs Cells cultured to 60 % confluency were incubated for 5 days with either complete culture medium alone (Control; open bar) or medium containing 7 mM CaCl 2, 7 mM β-GP (closed bars) or a combination of both (A). In parallel studies cells were incubated with 7 mM CaCl 2 plus 7 mM β-GP for different time points (C). Calcification was quantified and normalized for total cell protein as described in the Materials and methods section. The formation of calcific plaques was visualized under an inverted microscope at ×40 magnification and the photograph (B) is representative of at least three independent experiments. Changes in cell viability were determined as described in the Materials and methods section and represented in (D). The results are means + − S.E.M. from three experiments with five replicates in each. P < 0.05, P < 0.01 and P < 0.001 when compared with controls (C).
DISCUSSION
Although plasma constituents are believed to regulate VC, it is not entirely clear how the various molecules act, nor is the complex interplay among the key factors established. Furthermore, the critical role of each biomarker, in terms of which might be the most important molecule(s), remains unresolved. Of particular relevance to the present paper is the additional question about whether their presence in serum may be sufficient to regulate calcification outside of disease settings. If established, the latter may be of clinical significance in defining thresholds of calcific potential and predicting risks of calcification in vivo which might inform therapeutic strategies.
With the exception of studies by Chen et al. [5] demonstrating that pooled uraemic sera may accelerate calcification in bovine cultured vascular SMCs, there are no studies that have examined the direct calcific potential of non-pooled serum or its constituents in an in vitro setting. More importantly, the key question of whether the calcific potential of serum is dependent on the degree of renal impairment has not been addressed. We have therefore correlated the degree of in vitro calcification with the severity of renal impairment in vivo and have investigated the association between several biomarkers and the degree of calcification induced in vitro.
In developing our model, we examined the effects of calcium alone, phosphate in the form of β-GP and a combination of both at pre-determined concentrations. The degree of calcification was less pronounced with CaCl 2 and even less so with β-GP alone, but was clearly evident when both were used in combination. These results suggest that, on their own, neither CaCl 2 nor β-GP may be sufficient to induce profound calcification, at least in vitro. That this contradicts other studies may be due to differences in the duration of experiments, which in ours were over a shorter period (5 days). Others were prolonged, obtaining calcification after incubations of between 20 and 30 days [5, 12] . It is therefore likely that when used individually, CaCl 2 or phosphate may require a longer duration to cause calcification. The advantage of our model however is that calcification was significantly induced and evident within a period during which optimal cell confluency was maintained and viability was not compromised. Moreover, the process was time-dependent supporting the notion that it is regulated and not simply a consequence of aggregation of calcium and phosphate to form crystals. One conclusion we have not been able to draw from our studies is whether the changes we observed or from subjects with CKD3, CKD4/5 or on haemodialysis (closed bars). Calcification was quantified and normalized for total cell protein as described in the Materials and methods section. The results are means + − S.E.M. from three experiments with five replicates in each. P < 0.05, P < 0.01 and P < 0.001.
involved a change in phenotype or indeed differentiation of the cells into bone-like structures and this remains to be established. The results obtained with the clinical samples confirm that serum from CKD settings can induce calcification of normal healthy SMCs in vitro. Moreover, we have provided the first demonstration of this effect being graded, correlating well with the severity of renal impairment in vivo. In the first instance, the 5D sera had the most striking calcific potential, which was effectively 2-fold higher than the increases observed with the CKD3 or CKD 4/5 sera and at least 8-fold higher than the controls samples. With the limited sample size used in our studies, there was no notable difference in the effects obtained with the CKD3 and the CKD4/5 sera, but both were significantly higher than baseline values.
The events and mechanisms underlying the effects described above have not yet been investigated. Studies aimed at addressing Figure 3 Effects of CaCl 2 and β-GP on serum-induced calcification Cells cultured to 60 % confluency were incubated for 5 days with complete culture medium containing 10 % (v/v) control (open bar) or CKD sera in the absence (closed bars) and presence of CaCl 2 (7 mM) and β-GP (7 mM) (hatched bars). Calcification was quantified and normalized for total cell protein as described in the Materials and methods section. The results are means + − S.E.M. from three experiments with five replicates in each.
P < 0.01. Figure 4 Effects of CaCl 2 and β-GP on serum-induced calcification in responders and non-responders Cells cultured to 60 % confluency were incubated with (hatched bars) or without CaCl 2 (7 mM) and β-GP (7 mM) (closed bars) for 5 days in complete culture medium containing 10 % (v/v) serum from subjects on haemodialysis. Calcification was quantified and normalized for total cell protein as described in the Materials and methods section. The results are means + − S.E.M. from three experiments with five replicates in each.
P < 0.05.
these are now planned and will include analysis of fetuin A and FGF (fibroblast growth factor)-23, which are emerging as critical regulators of calcification [13] . In the interim we have analysed our samples for calcium and phosphate as well a number of other putative biomarkers of in vivo calcification and correlated these with the calcific potential of serum in our model. The first notable observation was that calcium was not significantly elevated above controls nor was it significantly different between the three CKD groups. Phosphate levels on the other hand increased relative to the degree of renal impairment and correlated positively with in vitro calcification. However, in our multivariate model, phosphate was not independently associated with calcific potential, suggesting that it may not be critical in this process. This would be consistent with our earlier demonstration that phosphate, on its own, is not sufficient to induce calcification in vitro over periods not associated with detrimental changes in cell survival and viability. Moe et al. [14] have also indicated that serum factors other than phosphate may be required for inducing calcification in vitro. These observations do not support other published literature [12, 15, 16] .
Blood urea, serum creatinine, PTH and OPG also increased in parallel with the severity of renal failure and correlated positively with calcific potential. Although serum creatinine was an independent predictor of calcific potential in our multivariate model, it is only a marker of renal dysfunction. PTH on the other hand remains controversial, with some studies claiming that elevated levels determine the severity and progression of VC [17] , whereas others have suggested that it may inhibit calcification [18] . To further compound the controversy, other groups have failed to establish a link between PTH and VC in patients with CKD [19, 20] . There was also no independent association of PTH with calcific potential in our multivariate model, suggesting that it is not directly involved in the process. Although OPG has been implicated as a key inhibitor of VC in animal models [21, 22] , levels are reported to be elevated in serum from CKD patients on dialysis [23, 24] and have been strongly correlated with the severity of coronary calcification [25, 26] . We found OPG to be independently associated with calcific potential in multivariate modelling, supporting a role in vitro and in the genesis of VC in humans.
Albumin decreased with advancing CKD and was negatively correlated with calcific potential with which it was independently associated in our multivariate analysis. This may still be a reflection of the severity of the degree of renal impairment, but may also indicate a regulatory role in the pathogenesis of VC perhaps by inhibiting calcification through attenuation of seeding of calcium phosphate crystals [27] . CRP and cholesterol which may have roles in the development of in vivo calcification [28] were associated with serum calcific potential in univariate analyses of our data. We did not however find evidence of an independent association, but this does not preclude a role for inflammation or lipid abnormalities in the in vitro model.
In parallel with establishing the direct effects of serum, we also explored whether their calcific potential could be enhanced by increasing calcium and phosphate concentrations in the incubation medium. Addition of CaCl 2 and β-GP failed to cause any significant change in basal calcium levels in the presence of control serum. This is an interesting and novel finding which strongly suggests that normal human serum is protective against calcification. The factors that may mediate this protection have not been fully investigated in the present study, but the biochemical data show high levels of serum albumin and of MGP which are known to negate calcification [29] and could explain, at least in part, our observations. The protective property of normal control serum appears to be lost in the moderate (CKD3) to advanced (CKD4/5) CKD states, where the presence of CaCl 2 and β-GP enhance serum calcific potential, presumably because of a change in the serum for a milieu more favourable to calcification. The increase did not exceed that seen previously with cells incubated with calcification buffer containing FBS and nor was it evident with serum from the haemodialysis cohort. This may be because of limiting factors that regulate the capacity for calcification in the in vitro setting.
The lack of enhancement of the calcific potential of 5D sera led us to examine individual samples more closely and this identified two distinct groups that we have referred to as responders and non-responders. The former showed decreased calcific potential when compared with the non-responders. However, the calcific potential of serum from responders could be enhanced by CaCl 2 and β-GP which was not evident with serum from non-responders. Further analysis of the biochemical parameters revealed that non-responders had significantly lower levels of BAP, HDL, RANKL and MGP. Phosphate levels were higher and albumin levels were lower in this group, but not significantly so. It may be that, in non-responders, the potential to calcify is already maximal and the addition of extra calcium and phosphate does not enhance calcification any further. In contrast, in responders, perhaps associated with higher ambient levels of inhibitors (e.g. HDL, MGP, RANKL and albumin) and lower levels of promoters (i.e. phosphate), the potential to calcify is sub-maximal. Thus, addition of extra calcium and phosphate further enhanced the degree of calcification in this group. However, when balanced with the lack of enhancement in the non-responders, the overall effect showed no difference between cells treated with 5D serum alone and those incubated with serum together with CaCl 2 and β-GP.
In summary, we have developed a model of VC which we have exploited to demonstrate the calcific potential of serum and shown that this correlated with the degree of uraemia in patients. The model appears suitable for screening clinical samples and offers a reproducible but yet simple system that could be employed in predicting risks of calcification in vivo. In addition, the model can now be utilized to identify critical biomarker surrogates and mechanisms responsible for the calcific potential of the serum. This may lead to the development of diagnostic tools and inform therapeutic strategies.
CLINICAL PERSPECTIVES
r The aim of the present study was to establish whether serum from subjects with CKD has the potential to induce calcification outside of the disease setting. This was with a view to identifying biomarker surrogates and mechanisms that could inform therapeutic strategies.
r The experiments conducted used serum from age-and sex-matched subjects with and without advancing CKD to induce calcification in cultured vascular SMCs. The results revealed that uraemic serum induces graded calcification that reflects the degree of kidney impairment in vivo. The effects had a positive correlation with serum creatinine, albumin and OPG, which were identified as significant predictors of the process in vitro.
r These findings show that serum from CKD settings has calcific potential outside of the disease milieu and may be of important clinical relevance in defining thresholds of calcific potential and predicting risks of calcification in vivo which might inform therapeutic strategies.
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